Pituitary tumor endocrinopathies and their endocrine evaluation

Neurosurgery Clinics of North America

Volumn 14, Issue 1, 2003, Pages 41-54

  Simard, Marie F ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GROWTH HORMONE; PROTIRELIN; SOMATOMEDIN; THYROTROPIN;

AGE; BLOOD ANALYSIS; CELL TYPE; CORTICOTROPIN RELEASE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENDOCRINE DISEASE; ENDOCRINE FUNCTION TEST; EVALUATION; GENDER; GONADOTROPIN RELEASE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERCORTISOLISM; HYPERTHYROIDISM; HYPOGONADISM; HYPOPHYSIS TUMOR; MICROADENOMA; ORAL GLUCOSE TOLERANCE TEST; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; SYMPTOMATOLOGY; THYROTROPIN RELEASE;

ACROMEGALY; ENDOCRINE GLAND NEOPLASMS; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MAGNETIC RESONANCE IMAGING; PITUITARY NEOPLASMS; PROLACTIN; THYROTROPIN;

EID: 0037269450     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1042-3680(02)00036-0     Document Type: Review

References (116)

1. Kunwar S, Wilson CB. Pediatric pituitary adenomas. J Clin Endocrinol Metab 1999;84:4385-9.
2. Terada T, Kovacs K, Stefaneanu L, et al. Incidence, pathology, and recurrence of pituitary adenomas: study of 647 unselected surgical cases. Endocr Pathol 1995;6:301-10.
3. Wenig BM, Heffess CS, Adair CF. Neoplasms of the pituitary gland. In: Wenig BM, Heffess CS, Adair CF, editors. Atlas of endocrine pathology. 1st edition. Philadelphia: WB Saunders; 1997. p. 11-29.
4. Burgess JR, Sheperd JJ, Parameswaran V, et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 1996;81:2642-6.
5. Jeffcoat WJ, Pound N, Sturrock NDC, et al. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol 1996;45:299-303.
6. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am 2001;30:585-609.
7. Weiss MH, Teal J, Gott P, et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983;12:180-3.
8. Faglia G. Prolactinomas and hyperprolactinemic syndrome. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th edition. Philadelphia: WB Saunders; 2001. p. 329-42.
9. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin. Clin Endocrinol 1998;48:547-53.
10. Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hock effect": case report. Neurosurgery 1998;42:913-6.
11. Petakov MS, Damjanovic SS, Nikolic-Durovic MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998;21:184-8.
12. St-Jean J, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol 1996;44:305-9.
13. Rand T, Kink E, Sator M, et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology 1996;38:744-6.
14. Molithc ME. Pituitary incidentilomas. Endocrinol Metab Clin North Am 1997;26:725-39.
15. Young WF Jr, Scheithauer BW, Kovacs KT, et al. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Foundation for Medical Education and Research 1996;71:649-56.
16. Snyder PJ. Gonadotroph adenomas. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia: WB Saunders; 2001. p. 313-20.
17. Greenman Y, Melmed S. Diagnosis and management of nonfunctioning pituitary tumors. Annu Rev Med 1996;47:95-106.
18. Christin-Maitre S, Rongieres-Bertrand C, Kottler M-L, et al. Clinical case seminar. A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. J Clin Endocrinol Metab 1998;83:3450-3.
19. Abrosi B, Basseti M, Ferrario R, et al. Precocious puberty in a boy with a PRL-, LH-, and FSH-secreting pituitary tumour: biosynthetic characterization and clinical studies. Acta Endocrinol 1990;122:569-76.
20. Faggiano M, Criscuolo T, Perrone I, et al. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol 1983;102:167-72.
21. Katznelson L, Alexander JM, Klibanski A. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993;76:1089-94.
22. Daneshdoost L, Gennarelli TA, Bashey HM, et al. Recognition of gonadotroph adenomas in women. N Engl J Med 1991;324:589-94.
23. Daneshdoost L, Gennarelli TA, Bashey HM, et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone β subunit response to thyrotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:1352-5.
24. Maroldo TV, Dillon WP, Wilson CB. Advances in diagnostic techniques of pituitary tumors and prolactinomas. Curr Opin Oncol 1992;4:105-15.
25. De Herder WW, Reijs AEM, Kwekkeboom DJ, et al. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand. Clin Endocrinol 1996;45:755-67.
26. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 1998;83:248-52.
27. Oppizi G, Cozzi R, Dallabonzana D, et al. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. J Endocrinol Invest 1998;21:512-9.
28. Plockinger U, Reichel M, Fett U, et al. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994;79:1416-23.
29. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41.
30. Abe T, Tara LA, Ludecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 1999;45:1-10.
31. Cheung NW, Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol 1997;47:323-7.
32. Colao A, Cuocolo A, Marzullo P. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 1999;84:1518-23.
33. Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol 1997;47:17-22.
34. Minniti G, Jaffrain-Rea ML, Moroni C, et al. Echocardiographic evidence for a direct effect of GH/IGF-1 hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol 1998;49:101-6.
35. Ozbey N, Oncul A, Bugra Z, et al. Acromegalic cardiomyopathy: evaluation on the left ventricular diastolic function in the subclinical stage. J Endocrinol Invest 1997;20:305-11.
36. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2001;30:565-81.
37. Schulz S, Redlich A, Koppe I, et al. Carney complex - an unexpected finding during puerperium. Gynecol Obstet Invest 2001;51:211-3.
38. Orme SM, McNally RJQ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730-4.
39. Cannavo S, Squadrito S, Finocchiaro MD, et al. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up. Horm Metab Res 2000;32:190-5.
40. Coalo A, Marzullo P, Gianfranco V, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1993;77:1352-5.
41. Coalo A, Marzullo P, Spiezia S, et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 1999;84:1986-91.
42. Colao A, Merola B, Ferone D, et al. Extensive personal experience. Acromegaly. J Clin Endocrinol Metab 1997;82:2777-81.
43. Grunstein RR, Ho KY, Sullivan CE, et al. Sleep apnea in acromegaly. Ann Intern Med 1991;115:527-32.
44. Isono S, Saeke N, Tanaka A, et al. Collapsibility of passive pharynx in patients with acromegaly. Am J Respir Care Med 1999;160:64-8.
45. Longobardi S, Di Somma C, Di Rella F, et al. Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest 1998;21:688-93.
46. Patel YC, Ezzat S, Chick CL, et al. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. Clin Invest Med 2000;23:172-87.
47. Perkins AT, Morgenlander JC. Endocrinologic causes of peripheral neuropathy. Postgrad Med 1997;102:81-106.
48. Quabbe H-J, Plockinger U. Metabolic aspects of acromegaly and its treatment. Metabolism 1996;45:61-2.
49. Russel-Jones DL, Weissberger AJ, Bowes SB, et al. The effect of growth hormone on protein metabolism in adult growth hormone deficient patients. Clin Endocrinol (Oxf) 1993;38:427-31.
50. Sacca L, Cittadini A, Colao A, et al. Growth hormone and the heart. Endocr Rev 1994;15:555-73.
51. Trotman-Dickenson B, Weetman AP, Hughes JMB, et al. Upper airflow obstruction and pulmonary function in acromegaly: relationship to disease activity. Q J Med 1991;79:527-33.
52. Balkany C, Cushing GW. An association between acromegaly and thyroid carcinoma. Thyroid 1995;5:47-50.
53. Jenkins PJ, Frajese V, Jones A-M, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85:3218-21.
54. Rajasoorya C, Holdawy M, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102.
55. Lie JT, Grossman ST. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 1980;100:41-52.
56. Randall RV, Scheithauer BW, Laws ER Jr, et al. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study of 97 patients operated on transsphenoidally. Mayo Clin Proc 1985;60:753-62.
57. Tendall H, Wales JK. Primary hyperthyroidism occurring in association with acromegaly. Br J Clin Pract 1989;43:177-9.
58. Cats A, Dullaart R, Kleibeuker JH, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996;56:523-6.
59. Ezzat S, Strom C, Melmed S. Colon polyps in acromegaly. Ann Intern Med 1991;114:754-5.
60. Furman K, Ezzat S. Psychological features of acromegaly. Psychother Psychosom 1998;67:147-53.
61. Herman-Bonert V, Seliverstov M, Melmed S. Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 1998;83:727-31.
62. Lee Vance M. Endocrinological evaluation of acromegaly. J Neurosurg 1998;89:499-500.
63. Melmed S. Evaluation of pituitary masses. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th edition. Philadelphia: WB Saunders; 2001. p. 282-8.
64. Guistina A, Barkan A, Casanueva F, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
65. Jasper H, Pennisi P, Vitale M, et al. Evaluation of disease activity by IGF-1 and IGF binding protein-3 (IGFBP3) in acromegalic patients distributed according to a clinical score. J Endocrinol Invest 1999;22:29-34.
66. Freda PU, Post KD, Powell JS, et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-16.
67. Meir CA, Biller BMK. Clinical and biochemical evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am 1997;26:741-62.
68. Belsky JL, Cuello B, Swanson LW, et al. Cushing's syndrome due to ectopic production of corticotropin-releasing factor. J Clin Endocrinol Metab 1985;60:496-500.
69. Schteingart DE, Lloyd RV, Akil H, et al. Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol Metab 1986;63:770-5.
70. Nieman LK. Cushing's syndrome. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th edition. Philadelphia: WB Saunders; 2001. p. 1691-15.
71. Jones KL. The Cushing syndromes. Pediatr Clin North Am 1990;37:1313-32.
72. Della CS, Corsello SM, Satta MA, et al. Intracranial and spine dissemination of an ACTH secreting pituitary neoplasia. Case report and review of the literature. Ann Endocrinol (Paris) 1997;58:503-9.
73. Young WF, Scheithauer BW, Gharib H, et al. Cushing's syndrome due to primary multinodular corticotrope hyperplasia. Mayo Clin Proc 1988;63:256-62.
74. Findling JW, Raff H. Diagnosis and differential diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 2001;30:729-45.
75. Shapiro MS, Shenkman L. Variable hormono-genesis in Cushing's syndrome. Q J Med 1990;79:351-63.
76. Mengden T, Habmann P, Mullen J, et al. Urinary free cortisol versus 17-hydroxycorticosteroids: a comparative study of their diagnostic value in Cushing's syndrome. Clin Invest 1992;70:545-8.
77. Newell-Price J, Trainer P, Besser M, et al. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998;19:647-72.
78. Tsigos C, Chrousos GP. Differential diagnosis and management of Cushing's syndrome. Annu Rev Med 1996;47:443-61.
79. Gorges R, Knappe G, Gerl H, et al. Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J Endocrinol Invest 1999;22:241-9.
80. Aron DC. Diagnostic implications of adrenal physiology and clinical epidemiology for evaluation of glucocorticoid excess and deficiency. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th edition. Philadelphia: WB Saunders; 2001. p. 1655-70.
81. Findling JW. Clinical application of a new immunoradiometric assay for ACTH. Endocrinologist 1992;2:360-5.
82. Streeten DHP, Fas FH, Elders MJ, et al. Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics 1975;56:797-803.
83. Nieman LK, Oldfield EH, Wesley R, et al. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of ACTH-dependent Cushing syndrome. J Clin Endocrinol Metab 1993;77:1308-12.
84. Doppman JL, Frank JA, Dwyer AJ, et al. Gadolinium DTPA enhanced imaging of ACTH-secreting microadenomas of the pituitary gland. J Comput Assist Tomogr 1988;12:728-35.
85. Bonelli FS, Huston J, Carpenter PC, et al. Adrenocorticotropic hormone-dependent Cushing's syndrome: sensitivity and specificity of inferior petrosal sinus sampling. AJNR Am J Neuroradiol 2000;21:690-6.
86. Findling JW, Kehoc ME, Shaker JL, et al. Routine inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab 1991;73:408-13.
87. Findling JW, Raff H. Newer diagnostic techniques and problems in Cushing's disease. Endocrinol Metab Clin North Am 1999;28:191-210.
88. Invitti C, Giraldi FP, de Martin M, et al. Inferior petrosal sinus sampling in patients with Cushing's syndrome and contradicting response to dynamic testing. Clin Endocrinol 1999;51:255-7.
89. Kaltsas GA, Giannulis MG, Newell-Price JDC, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999;84:487-92.
90. Landlot AM, Schubiger O, Maurer R, et al. The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease. Clin Endocrinol (Oxf) 1994;40:485-92.
91. Blevins LS Jr, Clark RV, Owens DS. Thromboembolic complications after inferior petrosal sinus sampling in patients with Cushing's syndrome. Endocr Pract 1998;4:365-7.
92. Doppman JL, Nieman LK, Chang R, et al. Selective venous sampling from the cavernous sinuses is not a more reliable technique than sampling from the inferior petrosal sinuses in Cushing's syndrome. J Clin Endocrinol Metab 1995;80:2485-9.
93. Doppman JL, Oldfield EH, Nieman LK. Bilateral sampling of the internal jugular vein to distinguish between mechanisms of adrenocorticotropic hormone-dependent Cushing's syndrome. Ann Intern Med 1998;128:33-6.
94. Beck-Peccoz P, Bruckner-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-38.
95. Bertholon-Gregoire M, Trouillas J, Guigard MP, et al. Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol 1999;140:519-27.
96. Bruckner-Davis F, Oldfield EH, Skarulis MC, et al. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999;84:476-86.
97. Shomali ME, Katznelson L. Medical therapy for gonadotroph and thyrotroph tumors. Endocrinol Metab Clin North Am 1999;28:223-40.
98. Burgess JR, Shepherd JJ, Greenaway TM. Thyrotropinomas in multiple endocrine neoplasia type 1 (MEN-1). Aust NZ J Med 1994;24:740-1.
99. Gessl A, Freissmuth M, Czech T, et al. Growth hormone-prolactin thyrotropin-secreting pituitary adenoma in atypical McCune-Albright syndrome with functionally normal Gsαprotein. J Clin Endocrinol Metab 1994;79:1128-34.
100. Chiovalo L, Barbesino G, Pinchera A. Graves' disease. In: DeGroot LJ, Jameson JK, editors. Endocrinology. 4th edition. Philadelphia: WB Saunders; 2001. p. 1422-49.
101. Calle-Pascual AL, Yuste E, Martin P, et al. Association of a thyrotropin-secreting pituitary adenoma and a thyroid follicular carcinoma. J Endocrinol Invest 1991;14:499-502.
102. Alings AMW, Fliers E, deHerder WW, et al. A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis. J Endocrinol Invest 1998;21:703-6.
103. Beck-Peccoz P, Persani L, Mantovani S, et al. Thyrotropin-secreting pituitary adenomas. Metabolism 1996;45:75-9.
104. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum TSH assays. Clin Chem 1996;42:140-5.
105. Gesundheit N, Petrick PA, Nissim M, et al. Thyrotropin-secreting pituitary adenomas. Clinical and biochemical heterogeneity. Case reports and follow-up of nine patients. Ann Intern Med 1989;111:827-35.
106. Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone α-subunit in pituitary adenomas. Trends Endocrinol Metab 1992;3:41-5.
107. Kamoi K, Mitsuma T, Sato H, et al. Hyperthyroidism caused by a pituitary thyrotropin-secreting tumor with excessive secretion of thyrotropin-releasing hormone and subsequently followed by Graves disease in a middle-aged woman. Acta Endocrinol (Copenh) 1985;110:373-82.
108. Faglia G, Beck-Peccoz P, Piscitelli G, et al. Inappropriate secretion of thyrotropin by the pituitary. Horm Res 1987;26:79-99.
109. Spada A, Bassetti M, Martino E, et al. In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine. J Endocrinol Invest 1985;8:193-8.
110. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid stimulating-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-40.
111. Losa M, Giovanelli M, Persani L, et al. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3086-90.
112. Bruckner-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with RTH. The NIH prospective study. Ann Intern Med 1995;123:572-83.
113. Refetoff S, Weiss RE, Usala SJ. The syndrome of resistance to thyroid hormone. Endocr Rev 1993;14:348-99.
114. Frank SJ, Gesundheit N, Doppman JL, et al. Preoperative lateralization of pituitary microadenomas by petrosal sinus sampling: utility in two patients with non-ACTH-secreting tumors. Am J Med 1989;87:679-82.
115. Lamberts SWJ, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-82.
116. Verhoeff NPLG, Bemelman FJ, Wiersinga WM, et al. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma. Eur J Nucl Med 1993;20:555-61.